Harnessing Genetically Engineered Bacteria for Human Insulin Production: A Molecular Transformation in Diabetes Therapy Insulin represents a fundamental hormone in metabolic regulation and constitutes the cornerstone of therapy for patients with Diabetes mellitus. This chronic metabolic disorder currently affects 537 million adults worldwide according to the 2023 International Diabetes Federation report, with projections reaching 643 million by 2030 and 783 million by 2045. The disease accounts for approximately 6.7 million deaths annually and imposes global healthcare expenditures exceeding 966 billion USD. Insulin is a peptide hormone composed of two polypeptide chains, A and B, linked by disulfide bridges and secreted by pancreatic β-cells. It regulates glucose uptake in peripheral tissues, modulates lipid and protein metabolism, and maintains systemic metabolic homeostasis. Failure of insulin production or action results in microvascular and macrovascular complications, making sustainable insulin production a critical global health priority. Historically, insulin was extracted from bovine and porcine pancreatic tissue following its discovery in 1921. Although structurally similar to human insulin, minor amino acid differences resulted in immunogenic reactions in a subset of patients and imposed limitations on large-scale production. The advent of recombinant DNA technology in the late 1970s revolutionized pharmaceutical biotechnology, culminating in the commercial release of recombinant human insulin in 1982. This milestone marked the beginning of the modern biopharmaceutical era and significantly enhanced product purity, scalability, and safety. Recombinant insulin production relies on precise molecular cloning techniques. The human insulin gene encoding proinsulin is synthesized or isolated and inserted into a circular plasmid vector using restriction enzymes and DNA ligase. This recombinant plasmid is introduced into host cells, most commonly Escherichia coli, chosen for its rapid growth kinetics, low production cost, and well-characterized genetics. Transformed bacterial cells express the human gene and produce insulin precursors in large-scale bioreactors. Subsequent purification processes, including chromatographic separation and controlled protein folding, yield highly pure pharmaceutical-grade insulin. Alternatively, eukaryotic expression systems such as Saccharomyces cerevisiae are employed to facilitate post-translational processing more analogous to human cellular mechanisms. Beyond insulin, recombinant DNA technology has enabled the production of clotting factors VIII and IX, recombinant growth hormone, erythropoietin, cytokines, therapeutic enzymes, and recombinant vaccines. The global insulin market alone exceeds 20 billion USD annually, serving more than 100 million insulin-dependent individuals. Recombinant insulin significantly reduced immunogenicity compared with animal-derived preparations and allowed the development of insulin analogs with modified pharmacokinetics, thereby improving glycemic control and reducing long-term complications. In conclusion, genetically engineered bacterial production of human insulin stands as one of the most transformative achievements in molecular medicine. It exemplifies the successful translation of genomic knowledge into life-saving therapeutics and laid the foundation for the modern biopharmaceutical industry. Continued advancements in gene editing, bioprocess engineering, and synthetic biology are expected to further enhance production efficiency, accessibility, and therapeutic innovation in the decades ahead.